Deal Watch: Roche Links With SemaThera, Acquires GenMark Diagnostics
Executive Summary
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
You may also be interested in...
Amgen Ropes Second M&A Deal Of 2021 In Rodeo Buyout
Deal snapshot: Rodeo’s preclinical work in modulating the 15-PDGH enzyme may yield novel regenerative therapies for inflammation, Amgen says, including GI and post-bone marrow transplant indications.
Aptevo Offloads Ruxience Biosimilar Rights In $67.5m Deal
The royalties for Pfizer’s Ruxience biosimilar, which has achieved a near 25% penetration rate in the US market, are to fall into the hands of another party following an agreement by original holder Aptevo Therapeutics. Teva’s Truxima is reported to be market leader in the US.
Pyxis’s $152m Series B Will Push Trio Of ADCs Toward Clinic
Pyxis says its three preclinical ADCs, acquired from Pfizer and LegoChem, offer immunomodulatory effects as well as direct killing of tumor cells. It hopes all three will reach Phase I in 2022.